13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001819257
Total reported value
$645.5M
$645.5M
20 檔
32.8%
As reported in its official Q4 2024 Form 13F filing, Patient Square Capital LP's tracked investment portfolio stood at $645.5M with 20 total positions.
In Q4 2024, Patient Square Capital LP displayed an active expansion posture, initiating 9 new positions and adding to 9 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 55.22% | +3.84% | +2.06% | |
| 2 | LQDA | Liquidia CORP | Stock-Other | 8.18% | — | -74.10% | |
| 3 | INSM | Insmed Inc | Stock-Healthcare | 7.93% | -4.57% | EXIT | |
| 4 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 4.00% | — | +6.57% | |
| 5 | EYPT | Eyepoint Inc | Stock-Other | 3.93% | -0.22% | +3.55% | |
| 6 | NRIX | Nurix Therapeutics Inc | Stock-Other | 3.14% | — | +36.99% | |
| 7 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.25% | — | — | |
| 8 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.89% | +0.28% | +147.36% | |
| 9 | GERN | Geron CORP | Stock-Other | 1.75% | — | — | |
| 10 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.50% | — | +99.97% | |
| 11 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.50% | — | — | |
| 12 | PHVS | Pharvaris N.V. | Stock-Other | 1.49% | +1.13% | -14.33% | |
| 13 | IRON | Disc Medicine Inc | Stock-Other | 1.34% | — | — | |
| 14 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.26% | — | — | |
| 15 | ALLO | Allogene Therapeutics Inc | Stock-Other | 1.19% | +0.14% | — | |
| 16 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.00% | +0.95% | — | |
| 17 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.94% | — | +67.99% | |
| 18 | ARVN | Arvinas Inc | Stock-Other | 0.62% | — | — | |
| 19 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.52% | — | — | |
| 20 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.35% | — | +166.49% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | +3.3% | +78.89% | Add |
| 2 | ROIV | Roivant Sciences Ltd. | +2.8% | +2.06% | Add |
| 3 | ITCIEUR | Intra-cellular Therapies Inc | +2.3% | NEW | New buy |
| 4 | GERN | Geron CORP | +1.8% | NEW | New buy |
| 5 | AGIO | Agios Pharmaceuticals Inc | +1.5% | NEW | New buy |
| 6 | IRON | Disc Medicine Inc | +1.3% | NEW | New buy |
| 7 | SWTXUSD | Springworks Therapeutics Inc | +1.3% | NEW | New buy |
| 8 | ALLO | Allogene Therapeutics Inc | +1.2% | NEW | New buy |
| 9 | ELVN | Enliven Therapeutics Inc | +1% | +147.36% | Add |
| 10 | MIRM | Mirum Pharmaceuticals Inc | +1% | NEW | New buy |
| 11 | OCUL | Ocular Therapeutix Inc | +0.7% | +99.97% | Add |
| 12 | ARVN | Arvinas Inc | +0.6% | NEW | New buy |
| 13 | SRRK | Scholar Rock Holding CORP | +0.5% | NEW | New buy |
| 14 | NRIX | Nurix Therapeutics Inc | +0.4% | +36.99% | Add |
| 15 | CATBUSD | Astria Therapeutics Inc | +0.2% | +166.49% | Add |
| 16 | NTLA | Intellia Therapeutics Inc | 0% | +67.99% | Add |
| 17 | EYPT | Eyepoint Inc | -0.1% | +3.55% | Add |
| 18 | PHVS | Pharvaris N.V. | -0.2% | -14.33% | Trim |
| 19 | CGEM | Cullinan Therapeutics Inc | -1.1% | +6.57% | Add |
| 20 | LQDA | Liquidia CORP | -18.5% | -74.10% | Trim |
According to official SEC Form 13F filings, Patient Square Capital LP reported a total U.S. public equity portfolio value of $645.5M across 20 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ROIV, LQDA, INSM) accounted for 32.8% of total reported equity market value during Q4 2024.
Top New Position Initiated
ITCIEUR
市值: $6.0M
Top Position Liquidated / Trimmed
LQDA
前期市值: $71.8M
During Q4 2024, Patient Square Capital LP's top holdings by market value included ROIV (55.2%)、LQDA (8.2%)、INSM (7.9%). The largest single position, ROIV, represented 55.2% of total portfolio value.
In Q4 2024, Patient Square Capital LP made 20 total portfolio adjustments, initiating 9 new buys, adding to 9 positions, trimming 2 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.